At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Leading innovation with gene editing, developing breakthrough therapy and benefiting all mankind". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 19 Investigator-Initiated clinical Trials (IIT) in 20 leading hospitals in China, 6 projects having received IND approvals, with many pipeline projects have entered into IND application stage.
